ArticleFrontiers in public health2026
Pneumococcal community-acquired pneumonia in hospitalized adults in México 2018-2021: serotype distribution and clinical characteristics.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Community-acquired pneumonia (CAP) in adults represents a significant burden on the healthcare system in México, particularly among high-risk groups. Materials and methods: Adults hospitalized with chest X-ray-confirmed CAP (2018-2021) were prospectively enrolled across four cities in México (Mexico City, Durango, Mérida, and Tijuana). Urine samples were screened for Results: Of the 1,275 patients screened for CAP, 389 had clinically or radiologically confirmed CAP (65.3% male; median age, 60 years; 39.3% aged ≥65 years). Pneumococcal CAP (pCAP) was identified in 12.1% of patients (47/389; 95% CI: 9.01-15.74). Based on CRB-65 scores, pCAP was more frequent among high-risk CAP patients (25.5%, 12/47) than among low- or moderate-risk CAP patients (10.2%, 35/342). Nevertheless, the 30-day mortality rate was 34.0% among pCAP patients versus 29.5% among Conclusion: During the study period, CAP was associated with a substantial mortality burden among hospitalized adult patients in México, with pCAP more frequent among high-risk patients. These findings underscore the needs for enhanced diagnostic approaches and risk group-targeted adult pneumococcal vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.